Adj TC + Herceptin Early Stage Breast Cancer

• Status: Completed
• Trial end date: 2013-04-01

Summary

The purpose of this research study is to find out what effects (good and bad) docetaxel/cyclophosphamide (brand names: Taxotere and Cytoxan, or TC) plus trastuzumab (brand name: Herceptin, or H) has HER2+ breast cancer.

• Phase: Phase 2

Details

• Lead Sponsor: US Oncology Research
• Collaborator: Sanofi
• Treatments: Cyclophosphamide; Docetaxel; Trastuzumab